Mera Pharmaceuticals, Inc.
MRPI
$0.00
$0.000.00%
OTC PK
| 10/31/2011 | 07/31/2011 | 04/30/2011 | 01/31/2011 | 10/31/2010 | |
|---|---|---|---|---|---|
| Revenue | -0.31% | 29.36% | 42.18% | -32.85% | -34.73% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.31% | 29.36% | 42.18% | -32.85% | -34.73% |
| Cost of Revenue | -93.84% | -- | 12.09% | 169.23% | 178.91% |
| Gross Profit | 116.49% | 28.91% | 47.42% | -35.62% | -66.63% |
| SG&A Expenses | 185.47% | 66.84% | 13.98% | 18.15% | -49.26% |
| Depreciation & Amortization | -63.16% | -81.08% | -80.88% | -34.88% | -71.21% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.08% | -10.69% | -12.39% | -12.74% | -22.54% |
| Operating Income | -29.34% | 61.79% | 53.50% | -71.00% | 9.08% |
| Income Before Tax | 73.51% | 63.45% | 52.96% | -65.65% | -263.02% |
| Income Tax Expenses | 15.00% | 25.53% | 20.41% | 39.29% | 57.45% |
| Earnings from Continuing Operations | 74.10% | 67.15% | 54.88% | -99.43% | -293.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 74.10% | 67.15% | 54.88% | -99.43% | -293.03% |
| EBIT | -29.34% | 61.79% | 53.50% | -71.00% | 9.08% |
| EBITDA | -36.29% | 56.76% | 50.80% | -95.21% | -8.93% |
| EPS Basic | 75.00% | 100.00% | 0.00% | -- | -300.00% |
| Normalized Basic EPS | 0.00% | 100.00% | 100.00% | -- | 0.00% |
| EPS Diluted | 75.00% | 100.00% | 0.00% | -- | -300.00% |
| Normalized Diluted EPS | 0.00% | 100.00% | 100.00% | -- | 0.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |